Post-earnings recap
Reported
Mon, May 6, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report reflects ongoing challenges for Ultragenyx Pharma, particularly in achieving profitability as indicated by the negative EPS. The stock reacted by declining 1.09%, likely due to investor concerns over the lack of revenue details and guidance. The cautious tone from management suggests that investors should brace for continued volatility as the company navigates its financial hurdles.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.82 | N/A | -3.95% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding the company's financial trajectory. They acknowledged the difficulties faced in the quarter.
Management highlighted ongoing challenges in achieving profitability.
They emphasized a focus on long-term growth despite current setbacks.